89bio to Present at Upcoming Investor Conferences
May 08 2020 - 7:30AM
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical
company focused on the development and commercialization of
innovative therapies for the treatment of liver and
cardio-metabolic diseases, today announced that Rohan Palekar, the
company’s Chief Executive Officer, will participate in a fireside
chat at the BofA Securities 2020 Virtual Global Healthcare
Conference on Thursday May 14, 2020 at 11:00 AM ET and the RBC
Capital Markets 2020 Global Healthcare Virtual Conference on
Wednesday, May 20, 2020 at 3:05 PM ET.
The live and archived webcast of the
presentation will be accessible from the company’s website at
https://ir.89bio.com/events-and-presentations. The replay of the
webcast will be available on the company’s website.
About 89bio
89bio is a clinical-stage biopharmaceutical
company focused on the development and commercialization of
innovative therapies for the treatment of liver and
cardio-metabolic diseases. The company’s lead product candidate,
BIO89-100, is being developed for the treatment of NASH. The
company also intends to develop BIO89-100 for the treatment of
SHTG. BIO89-100 is a specifically engineered glycoPEGylated analog
of FGF21 that is currently in a proof of concept Phase 1b/2a
clinical trial in patients with NASH or NAFLD and a high risk of
NASH. 89bio is headquartered in San Francisco with operations in
Herzliya, Israel. Visit 89bio.com for more information.
Forward-Looking Statements
Certain statements in this press release may constitute
"forward-looking statements" within the meaning of the federal
securities laws, including, but not limited to, 89bio’s
expectations regarding plans for its clinical programs and clinical
trials, the association of preclinical data with potential clinical
benefit and timing of anticipated milestones. Words such as “may,”
“might,” “will,” “objective,” “intend,” “should,” “could,” “can,”
“would,” “expect,” “believe,” “design,” “estimate,” “predict,”
“potential,” “develop,” “plan” or the negative of these terms, and
similar expressions, or statements regarding intent, belief, or
current expectations, are forward-looking statements. While 89bio
believes these forward-looking statements are reasonable, undue
reliance should not be placed on any such forward-looking
statements, which are based on information available to us on the
date of this release. These forward-looking statements are based
upon current estimates and assumptions and are subject to various
risks and uncertainties (including, without limitation, those set
forth in 89bio’s filings with the U.S. Securities and Exchange
Commission (SEC)), many of which are beyond 89bio’s control and
subject to change. Actual results could be materially different.
Risks and uncertainties include: expectations regarding the
enrollment, completion and outcome of 89bio’s Phase 1b/2a proof of
concept clinical trial evaluating BIO89-100 in patients with NASH
or patients with NAFLD and a high risk of NASH; expectations
regarding the timing, completion and outcome of 89bio’s proof of
concept Phase 2 clinical trial evaluating BIO89-100 in patients
with SHTG; the unpredictable relationship between preclinical study
results and clinical study results; the effect of the COVID-19
pandemic on 89bio’s clinical trials and business operations; and
other risks and uncertainties identified in 89bio’s Annual Report
on Form 10-K for the year ended December 31, 2019, filed March 18,
2020 with the SEC and other subsequent disclosure documents filed
with the SEC. 89bio claims the protection of the Safe Harbor
contained in the Private Securities Litigation Reform Act of 1995
for forward-looking statements. 89bio expressly disclaims any
obligation to update or alter any statements whether as a result of
new information, future events or otherwise, except as required by
law.
Investor Contact: Ryan Martins Chief Financial
Officerinvestors@89bio.com
Media Contact: Lori Rosen LDR Communications
917-553-6808lori@ldrcommunications.com
89bio (NASDAQ:ETNB)
Historical Stock Chart
From Mar 2024 to Apr 2024
89bio (NASDAQ:ETNB)
Historical Stock Chart
From Apr 2023 to Apr 2024